Abstract: Peptide aptamers are combinatorial protein molecules with specific bind affinity to given target proteins under intracellular conditions. The typical structure of peptide aptamers is a short peptide region inserted within a scaffold protein. The short peptide region is responsible for binding with its target protein and the scaffold protein helps to enhance the binding affinity and specificity through restriction on the conformation of the binding peptide. This unique structural feature allows peptide aptamers to bind with their target proteins with strong affinity and high specificity. Applications of peptide aptamers thus vary from in vitro detection of various proteins in a complex mixture to in vivo modulation on proteins and cell functions. Peptide aptamers have also been considered as therapeutic molecules because of their anticancer and antivirus activity. Due to the importance of peptide aptamers, a general review on the structure, selection and applications of peptide aptamers in biological study as well as in therapeutics will be presented in this paper.
INTRODUCTION
Peptide aptamer is a term created by analogy to DNA/RNA aptamer. Unlike DNA/RNA aptamers, peptide aptamers are combinatorial protein reagents instead of oligonucleotides. And the target for peptide aptamers so far has been focused on protein instead of a wide range of biomolecules as for DNA/RNA aptamers. Peptide aptamers can bind to their target proteins with strong affinity and high specificity. Compared with antibodies, peptide aptamers are smaller in size but possess similar binding ability and recognition property to their target proteins both in vitro and in vivo. Although research interest on peptide aptamers was far less than that on DNA/RNA aptamers in the past decades, the application of peptide apatmers is now emerging as an attractive topic for chemists as well as biologists in recent years [1] [2] [3] . Here we will give a brief review on recent studies on peptide aptamers, with an emphasis on the applications of peptide aptamers on therapeutics.
Peptide aptamers are combinatorial protein molecules with variable peptide sequences inserted within constant scaffold proteins. Representative structure of peptide aptamers will be introduced in the first part. Identification of peptide aptamers is typically performed under stringent yeast dihybrid conditions, which enhances the probability for the selected peptide aptamers to be stably expressed and correctly folded in an intracellular context. Representative methods for selection and identification of peptide aptamers will be introduced in the second part. Peptide aptamers are able to discriminate between closely related members within a protein family or even between different allelic variants of a protein, which is very important for the therapeutic applications of peptide aptamers. Representative examples on the biological and therapeutic applications of peptide aptamers will be reviewed as the major part of this paper.
STRUCTURE OF PEPTIDE APTAMERS
The typical structure of peptide aptamers is a peptide loop inserted into a scaffold protein as shown in Fig. (1) . The inserted peptide loop usually contains 8 to 20 amino acids [4] . The variable peptide loop inserted can be isolated from randomized libraries, or can be amino acid sequences taken from previously identified proteins. Insertion of the peptide sequence into the scaffold protein results in doubly constrained peptide. The construct of the doubly constrained peptide aptamers is realized by the insertion of oligonu-*Address correspondence to this author at the Institute of Chemical Biology and Drug Innovation, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing University, 22 Hankou Road, Nanjing 210093, China; Tel: 86-25-83593072; Fax: 86-25-83685976; E-mail: njuzy@nju.edu.cn cleotides encoding the peptide sequence into existing or engineered restriction sites in the open reading frame encoding the scaffold protein [5, 6] . The insertion site on the scaffold protein should be chosen where the insertion of peptide could deactivate the enzymatic activity of the original scaffold protein and to block its interaction with any cellular molecule or organelle. After insertion into the scaffold, the peptide loop responsible for target binding should be displayed on the solvent-exposed surface of the scaffold protein.
The final shape of the inserted peptide is determined not only by the amino acid residues and sequence of the peptide, but also by the primary sequence and tertiary structure of the scaffold protein. The doubly constrained peptide through fusion to the scaffold protein at both termini could have 10 2 -10 3 fold higher affinity to its target protein than unconstrained peptides [7] . The three-dimensional folding of the scaffold could provide limited conformational space and thus force the peptide to adopt a discrete shape. An ideal scaffold protein should be biologically inert and have no enzymatic activity. One of the common scaffold proteins in the peptide aptamer system is the E. coli thioredoxin A protein (TrxA) [5] , in which the variable peptide moiety is introduced into a loop within the biologically active center of the protein. Other scaffold proteins that have been used in peptide aptamers include the inactived staphylococcal nuclease [8] , the protease inhibitor eglin C [9] , the cellular transcription factor Sp1 [10] , and the green fluorescent protein (GFP) [11] . There were comparisons on different scaffold proteins based on binding analyses, for which peptide moieties were transferred from defined TrxA-based peptide aptamers to alternative scaffold proteins such as the green fluorescent protein and staphylococcal nuclease [12] . Binding analyses revealed that the TrxA scaffold was the optimal choice for many peptide aptamers. Recently a new peptide scaffold protein called Stefin A triple mutant (STM) was designed and it was able to present peptides that bound to targets of interest both in the context of known interactions and in library screening [13] .
SELECTION OF PEPTIDE APTAMERS
Peptide aptamers are commonly selected from randomized libraries. One of the screening strategies for peptide aptamers is adapted from the screening procedure used in the traditional yeast two-hybrid system [14] . The principle of this screening strategy is that a DNA-binding domain (BD) of a yeast transcription factor and a transcriptional activation domain (AD) are able to form a transcription factor only when they are brought together. Once the transcription factor is formed, it can bind to the upstream activating sequence (UAS) of the reporter gene and subsequently induce reporter gene expression. Therefore in the peptide aptamer screening system, the target protein (TP) of the peptide aptamer is linked with BD and expressed as "bait" in the yeast. As shown in Fig. (2) , the peptide aptamer candidate with scaffold protein is linked to AD and expressed as "prey". The BD and AD will be brought together to form a transcription factor only if the peptide aptamer can bind to the target protein. This transcription factor will then activate the promoter of the reporter gene and lead to reporter gene expression. Through detection of selected gene expression such as luciferase expression [15] , peptide aptamers which can bind to the target protein will be identified. So far it is the most commonly used strategy for selection of peptide aptamers.
Up to now there are four types of peptide aptamer libraries: yeast two-hybrid libraries, yeast expression libraries, bacterial expression libraries and retroviral libraries for expression in mammalian cells [6] . In contrast to common screening methods such as phage display, the methods used for selection of peptide aptamers were under intracellular conditions. Therefore it allows the preselection for molecules which are stable and can bind to their targets in living cells. Peptide aptamers selected therein have the advantage of detecting interactions taking place under intracellular conditions, which is of particular importance for functional studies within cells.
APPLICATIONS OF PEPTIDE APTAMERS
Compared with antibodies, peptide aptamers have similar or even higher binding affinity to their protein targets. Thus they can find many applications as antibodies do. Moreover, different from antibodies which are relatively large and not optimal for intracellular applications, peptide aptamers are able to compete for endogenous protein-protein interactions in living cells because of their unique structure as well as strong affinity to the intracellular target proteins. Therefore, peptide aptamers can be applied not only to "forward studies", such as phenotypic screens or microarrays, but also to a range of "reverse" studies where they can act as a probe to the protein of interest for investigation on all aspects of its biology. The application of peptide aptamers in cell biology as well as for therapeutics is an emerging research area. Recent examples on the applications of peptide aptamers ranging from protein detection, protein function modulation to therapeutic applications will be reviewed herein.
Protein Detection
Peptide aptamers have been used in label-free protein detection techniques such as protein microarrays. For such applications, peptide aptamers with recognition moiety constrained by a robust scaffold protein such as STM make it possible to construct interfaces capable of specific, stable, sensitive and designable recognition of specific proteins. Upon introduction of a cystein residue to STM, the resulted isoform STM-Cys + enabled oriented immobilization of the peptide aptamer on gold surface [16] . It has been demonstrated that there is a strong relationship between the binding affinity of the peptide aptamer to its protein target and the orientation of the peptide aptamer immobilized on the gold surface [17] . With one single cystein residue present in the scaffold protein and located at the opposite side to the peptide insert region, the peptide aptamer displayed by the STM-Cys + scaffold showed oriented and specific immobilization on gold surface (Fig. 3) . The properly immobilized peptide aptamer was able to bind with high affinity and specificity to the cyclin-dependent protein kinases (CDKs) which played important roles in proliferating and cancer cells. The surface- Fig. (2) . Illustration on the screening of peptide aptamers based on the yeast-two-hybrid screening system. In principle, the system consists of three components: A bait consisting of TP that fused to BD; A prey consisting of a peptide aptamer candidate (PA) linked to AD; A genetically modified yeast strain containing reporter gene under the transcriptional control of the binding sites for BD (UAS). Without the binding between BD and AD or bait and prey, the reporter gene will not express (Fig. 2a) . When the PA binds to TP, the BD and AD are brought in close proximity and the resulted transcription factor will activate the promoter of the reporter gene and lead to reporter gene expression ( 
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immobilized peptide aptamer was able to detect its target protein CDK2 in a complex sample containing CDK2 with nanomolar concentration [18] . Specific recognition of CDKs in whole-cell lysates was realized by using arrays of ten electrodes functionalized with individual peptide aptamers without any cross-talk between electrodes [19] . Integrated with extended gate metaloxidesemiconductor field-effect transistors, peptide aptamers targeting CDK family were used for label-free sub-picomolar protein detection [20] .
The relatively uniform scaffold protein for potentially many thousands of arrayed peptide aptamers is predicted to simplify the production of microarrays. The STM-based surface-immobilized peptide aptamers have been demonstrated as viable probe molecules for protein array applications. A set of peptide aptamers specific for the human papillomavirus (HPV) type 16 oncoproteins E6 and E7 has been used in a microarray format [21] . Peptide aptamer microarrays are shown to detect low levels of E6 and E7 proteins in fluorescence-labeled lysates generated from HPV-infected cervical keratinocytes expressing both E6 and E7 oncoproteins. Therefore peptide aptamer microarray could serve as a promising tool not only for proteomics, but also for biological and clinical investigations of cervical carcinogenesis.
Many cellular proteins can also be detected by peptide aptamers. Peptide aptamers against paired amphipathic helix (PAH) were able to characterize sin3 PAH-domain interactor specificity and to identify PAH partners [22] . Peptide aptamers embedded onto a protein microarray matrix have been used for detection and quantification of anterior gradient-2 (AGR-2) protein from crude clinical biopsy lysates [23] . A recent example of RNA/peptide dual aptamer has been demonstrated as a direct electrochemical impedance spectroscopy sensor for simultaneous detection of both PSMA (+) and PSMA (-) cells by electrochemical impedance spectroscopy [24] . An anti-PSMA RNA aptamer A10 for the PSMA (+) cell line and a DUP-1 peptide aptamer (FRPNRAQDYNTN) for the PSMA ( ) cell line, were conjugated to streptavidin to form the dual-aptamer probe on the surface of the Au working electrode. Detection of prostate cancer cells was realized by increased impedance because of difficulty of charge transfer through physical blocking by bound cells to the aptamer probe on the electrode surface.
Protein Function Modulation
Peptide aptamers can bind to their targets at the intracellular level with high specificity and strong affinity, which provides a new experimental strategy for protein function modulation both in vitro and in vivo [25] . Early functional studies using peptide aptamers targeting CDK2 revealed that these aptamers were able to specifically block CDK2/cyclin E kinase-mediated phosphorylation of histone H1 in vitro with apparent half-inhibitory concentrations ranging from 1.5 to 100 nM [5] . Further investigation on one of the CDK2-targeting molecules showed that it could interfere with CDK2-mediated phosphorylation of histone H1, but not with CDK2-mediated phosphorylation of Rb [9] . Peptide aptamer Pi101 was found to inhibit cathepsin E (CE) with an inhibition activity comparable to that of the potent CE inhibitor pepstatin A. And the inhibition of Pi101 was specific on CE since it did not inhibit cathepsin D which is structurally similar to CE [26] . Peptide aptamer pBMT101 could interfere with thymidylate synthase (ThyA) in vivo and inhibit intracellular process in bacterial [27] .
Peptide aptamers used for modulation on protein functions inside cells can always induce downstream responses [25, 28] . Peptide aptamer Apt48 was selected as the antagonist for the transcription factor BCL-6 which is essential for germinal center B-cell development. Apt48 could specifically bind to the Pox virus and zinc finger (POZ) domain of BCL-6 but not the POZ domains of other related proteins. Expression of Apt48 could increase the expression of the differentiation markers CD69, Blimp-1 and cyclin D2 in B-cell lines. It could also restore the cytokine-mediated growth arrest to BCL-6 overexpressing cells. Thus Apt48 could modulate the function of BCL-6 and further regulate the differentiation of proliferating B cells [29] . Three Smad binding peptide aptamers from the Smad-binding proteins CBP, FoxH1 and Lef1 inserted into the scaffold protein Trx have been used as tools to determine if disruption of specific Smad protein-protein interactions would selectively inhibit responses to TGF-or generally interfere with Smad-dependent signaling [30] . The results suggested that Smad-binding peptide aptamers could be developed to selectively inhibit TGF--induced gene expression.
Peptide aptamers can dissect molecular events mediated by individual protein domains. One example is the peptide aptamer "swiggle" that could interact with the short intracellular domain of membrane type 1-metalloproteinase (MT1-MMP) which is a key cell surface protease involved in numerous and crucial physiological and pathological cellular events [31] . Expression of swiggle in mammalian cells was found to increase the cell surface expression of MT1-MMP. Swiggle could interact with the internalization motif of MT1-MMP intracellular domain and disrupt the interaction required for endocytosis of the protease. Using peptide aptamers Pep2/141/22 which can distinguish allelic forms of H-Ras, the interaction of oncogenic Ras with c-Raf1 in vitro was inhibited and EGF-stimulated activation of c-Raf1 in vivo was abolished [32] .
Peptide aptamers have also been used as powerful tools to study protein interaction network and to elucidate signal transduction pathways [1] . Death-associated protein kinase (DAPK) is a multidomain enzyme that plays a central role in autophagic and apoptotic signaling. Peptide aptamer interaction screening has helped to elucidate the protein-protein interactions regulating DAPK functions which were not well defined before. A peptide aptamer interaction screen for the core kinase domain of DAPK successfully identified microtubule-assoicated protein 1B (MAP1B) as a novel interacting protein with DAPK [33] . Based on the peptide aptamer interaction screening set up for the DAPK death domain, tumor suppressor protein tuberin (TSC2) was identified as a novel DAPK death domain-binding protein [34] . A positive relation between growth factor stimulation of DAPK, the microtubule signaling pathway and mammalian target of rapamycin (mTORC1) signaling which may affect autophagy, cell survival or apoptosis was then uncovered.
Peptide aptamers selected to disrupt a biological process can be used as affinity reagents to identify individual proteins and protein interactions needed for the process. Using peptide aptamers as ''mutagens'' to identify genes, proteins and protein interactions needed for a complex phenotype, forward genetic analysis has proved to be particularly useful in elucidating genetic networks in organisms and processes for which classical genetics was not feasible [35] . Peptide aptamer PA207 which can bind to the second LIM domain of the transcription regulator LMO2 protein and disrupt its function was used in order to address the importance of LMO2 involved in human T-cell leukemia in tumor development [36] . It was found that the peptide aptamer inhibited LMO2 function in a mouse T-cell tumor transplantation assay by preventing LMO2-dependent T-cell neoplasia. Thus the role of LMO2 required for sustained T-cell tumor growth was discovered in addition to its preleukemic effect. Interference with LMO2 complexes was then considered as a strategy for controlling LMO2-mediated cancers. The finger structure of LMO2 also became an explicit focus for drug development.
Peptide aptamer P1 has been selected to assess the value of Casein kinase II (CK2) as a target of antiproliferative strategies [37] . P1 could bind to CK2 with high affinity and it was found to induce apoptosis in mammalian cells through the recruitment of a p53-dependent apoptosis pathway. Further study based on this result revealed that CK2 was critical for cell survival. The results indicated that inactivation of protein function by peptide aptamers helps to understand the control on signaling pathways and oncogenic missense alleles. A peptide aptamer was designed to inhibit the binding between Smad4 and lymphoid enhancer-binding factor 1/T cell specific factor (LEF/TCF) [38] . As a result, TGFindependent function for Smad4 in cooperating with LEF/TCF to activate c-myc expression was reported for the first time. Expression of two peptide aptamers which could recognize two essential CDKs, DmCDK1 and DmCDK2 in Drosophila disrupted normal eye development by inhibiting CDK function [39] . Expression of the peptide aptamers during organogenesis caused adult eye defects, typical of those caused by cell cycle inhibition.
Peptide Aptamers with Antiviral Activities
Peptide aptamers have been considered as a new class of molecules with antiviral activities. Using the peptide aptamer screening system, peptide aptamers which could block viral replication by interfering with capsid formation have been identified. From the peptide aptamers which could specifically bind to the hepatitis B virus (HBV) core protein under intracellular conditions, one peptide aptamer C1-1 emerged as a novel model compound for inhibiting HBV replication by blocking capsid formation [40] . Peptide aptamer PA34 has also been found to interact with the core protein which results in the removal of the core protein from the viral life cycle [41] . The study indicated that PA34 could induce a dramatic intracellular redistribution of its target protein into perinuclear inclusion bodies and lead to the typical characteristics of aggresomes, which also represents a novel mechanism as to how peptide aptamers act as intracellular inhibitors to block the function of their target proteins. Selection of peptide aptamers against the hepatitis C virus (HCV) using mRNA display has also been realized [42] . The mRNA display selection technology was combined with a simple and robust cyclization procedure to screen a peptide library and to isolate cyclic peptides that bind with high affinity and specificity to the internal ribosomal entry site (IRES) of HCV mRNA.
Peptide aptamers binding with other protein targets have also been selected as potential antiviral reagents. For example, A20 protein is a major component of the vaccinia virus replication complex. It binds to the DNA polymerase E9, the uracil DNA glycosylase D4 and the primase/helicase D5, three proteins that are essential for viral DNA synthesis. Therefore a yeast genetic approach has been developed to select 8-mers peptide combinatorial libraries for peptide aptamers that specifically interact with A20 [43] . Peptide aptamer 72 was identified from the library. Vaccinia virus DNA synthesis was impaired in cells constitutively expressing peptide aptamer 72 and virus production was inhibited in those cells. Besides, the viral serine protease NS3 was regarded as a prime target for anti-viral drugs. Therefore peptide aptamers which can inhibit NS3 have been isolated and used as another type of antivirus reagent [44] . The nonconventional nuclear localization signal of the essential viral replication factor pUL84 has also been regarded as target for peptide aptamer for antivirus activity [45] . Peptide aptamers which could specifically interfere with the nuclear import of pUL84 thus could act as a novel class of therapeutic reagents for antiviral purposes.
Peptide Aptamers with Anticancer Activities
Peptide aptamers have been selected to target proteins that are essential in cancer development and progression, which enables the important applications of peptide aptamers as anticancer molecules [46] . Up to now several types of cancer-related proteins have been used as peptide aptamer targets for anticancer activities. Proteins involved in the p53 tumor suppressor mediated pathway represent an important type of target proteins [37, 47, 48] . The epidermal growth factor receptor (EGFR) family regulates essential cellular functions and plays central roles in the progression of tumors, therefore peptide aptamers targeting EGFR related proteins have also been investigated [49] . Other emerging protein targets in cancer therapy include those related to HPVs [50, 51] , the differentiation or DNA binding (ID) proteins [52, 53] and human heat shock protein 70 (HSP70) [56] .
Oncogenic inhibition of the p53 tumor suppressor is one of the key features of human cancer, therefore reactivation of p53 holds promise as a therapeutic strategy for cancer treatment. A novel type of p53 inhibitor called AGR-2 has been proven to be able to reacti-vate p53 [47] . Peptide aptamers containing the core TxIYY pentapeptide sequence that can bind to AGR-2 were then selected and regarded as potential anticancer drug leads. Genetically selected peptide aptamers that specifically target the regulatory subunit of protein kinase CK2 has been proven to be able to induce apoptosis in mammalian cells through the recruitment of a p53-dependent apoptosis pathway [37] . Mutations in the p53 tumor suppressor gene also represent a key feature of human cancer. Expression of p53 point mutants could accumulate in cancer cells and actively collaborate with tumor progression. Peptide aptamers which are able to interact more efficiently with p53 conformational mutants compared with wild-type p53 were then isolated to reduce the transactivation activity of mutant p53 and to induce apoptosis specifically in cells expressing mutant p53 (Fig. 4) [48] . These peptide aptamers could provide a potential strategy to inhibit the oncogenic functions of mutant p53 and improve mutant p53-targeted cancer therapies.
Receptor tyrosine kinases of the EGFR family also play central roles in the progression of tumors. Peptide aptamers were identified from a random peptide library integrated into the thioredoxin scaffold protein, which specifically bind to the intracellular domain of the EGFR. Intracellular expression of the peptide aptamer encoding gene construct KDI1 or introduction of bacterially expressed KDI1 via a protein transduction domain into EGFR-expressing cells resulted in KDI1/EGFR complex formation, which led to a slower proliferation and reduced soft agar colony formation [49] . KDI1 did not block the EGFR tyrosine kinase activity but selectively interfered with the EGF-induced phosphorylation of Stat3. Stat3-dependent transactivation was then impaired and inhibition on the tumor cells growth was realized. Therefore these peptide aptamers have the potential to selectively inhibit specific aspects of EGFR signaling and might become valuable candidates for anticancer agents.
Peptide aptamers targeting the HPV E6 oncoprotein have been developed with therapeutic perspectives since certain types of HPVs are closely related to the development of human cancer [50] . It has been confirmed that intracellular targeting of the HPV16 E6 oncoprotein by E6-binding peptide aptamers resulted in the apoptotic elimination of HPV16-positive cancer cells but not on HPVnegative cells [51] . The HPV E6-targeting peptide aptamers therefore have implications for the development of therapeutic strategies for the treatment of HPV-associated dysplasias and cancers. Peptide aptamers targeting DNA binding proteins (Id1-4) which were found to be involved in tumor growth, invasiveness, metastasis, and angiogenesis have also been considered as anti-cancer molecules. Peptide aptamer Id1/3-PA7 isolated from randomized combinatorial expression library using yeast and mammalian two-hybrid systems could specifically interact with Id1 and Id3 and induce cell cycle arrest and apoptosis in breast cancer cells [52] as well as in ovarian cancer cells [53] . Thus the peptide aptamer Id1/3-PA7 could be considered as a nontoxic exogenous agent that can significantly provoke antiproliferative and apoptotic effects in cancer cells.
Peptide aptamer TRIP
E32G was designed to target the guanine nucleotide exchange factor (GEF) of the trio-related transforming gene in ATL tumor cells (Tgat) [54] . TRIP E32G specifically inhibited Tgat GEF activity in vitro and significantly reduced Tgatinduced RhoA activation. When cells expressing Tgat and TRIP
E32G
were subcutaneously injected into nude mice, formation of Tgatinduced tumors was subsequently reduced. Peptide aptamers selected to specifically interact with Hsp27 and not with the other members of the small heat shock protein family could perturb the dimerization and oligomerization of Hsp27. These peptide aptamers were found to be negative regulators of the anti-apoptotic and cytoprotective activities of Hsp27. As a result, use of these peptide aptamers in animal model could lead to strongly reduced tumor development through cell cycle arrest [55] . Peptide aptamers could also be used in combination with other anti-cancer drugs in order to achieve maximum therapeutic effect on cancer cells. For instance, two peptide aptamers targeting the peptide binding and ATP-binidng domains of HSP70 increased the sensitivity of the cells to apoptosis induced by anticancer drugs. The peptide aptamers specifically inhibited the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by anticancer drugs [56] . Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor were selected from a random peptide library using a yeast two-hybrid system with the intracellular tyrosine kinase domain of ErbB2 as a bait construct [57] . One selected peptide aptamer AII-7 was found to strongly inhibit the induction of AKT kinase in MCF7 breast cancer cells through interaction with the ErbB2 receptor. The peptide aptamer could inhibit the selected signaling functions without binding to the ATP-binding site and decrease the AKT phosphorylation on heregulin induction of the receptor dimer. Thus it restored sensitivity of breast cancer cells to the anti-cancer drugs.
Except for applications described above, other applications of peptide aptamers have also been explored. For peptide aptamers selected with therapeutic potential, they can be used for lead structures for protein drug design [25] . Peptide aptamers have also found many applications in therapeutic research, from target identification and validation to drug discovery [58] . Peptide aptamers with potential therapeutic applications are summarized in Table 1 . Further study on peptide aptamers can guide the discovery of small molecular drugs specific for the molecular surfaces on target proteins of pathological importance.
CONCLUSIONS AND FUTURE PERSPECTIVES
Peptide aptamers have been proven to be important biological probes as well as reagents with great potential in therapeutics. With the development on convenient method to select peptide aptamers targeting specific proteins under intracellular conditions, a large amount of peptide aptamers have been selected and identified. These peptide aptamers demonstrate great potential for applications not only for target protein detection, but also for modulation on cellular events regulated by their target proteins. Using peptide aptamers as tools to elucidate the function of given target proteins and their interactions in biological networks, novel therapeutic targets for drug discovery have also been identified. Peptide aptamers themselves also showed therapeutic potential as lead structures for the design of anti-viral or anti-cancer drugs. Peptide aptamer approach has the potential to identify inhibitors of virtually any target protein of biological or pathological significance, therefore they should have a broad impact on different areas of basic biological research and applied molecular medicine.
Peptide aptamers can be developed into more powerful tools in biological study as well as for therapeutic applications. New generation of peptide aptmers with higher specificity and stronger binding affinity toward target proteins is being explored. Novel computational system with fast and robust bind docking of a peptide to a fixed protein structure has been developed to predict the binding sites between a peptide aptamer and the protein surface, which may be useful for peptide aptamer design [59] . Regulation on the intracellular localization of peptide aptamers is another interesting field. By using combined hemagglutinin-2 subunit and nuclear localiza- tion signal peptides, Tat-conjugated peptide aptamers were selectively delivered into the nucleus [60] . The cytostatic activity of a Tat-fused p53-derived peptide aptamer against human MDM2 was found to be enhanced after nuclear targeting. It is also interesting to integrate the function of peptide aptamers with other techniques such as nano-carriers for wider applications [61] . Research on peptide aptamers is still in its infancy and there are a lot of potential applications of peptide aptamers waiting to be explored. 
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